BACKGROUND: Revision anterior cruciate ligament (ACL) reconstruction has worse outcomes than primary reconstructions. Predictors for these worse outcomes are not known. The Multicenter ACL Revision Study (MARS) Group was developed to perform a multisurgeon, multicenter prospective longitudinal study to obtain sufficient subjects to allow multivariable analysis to determine predictors of clinical outcome. PURPOSE: To describe the formation of MARS and provide descriptive analysis of patient demographics and clinical features for the initial 460 enrolled patients to date in this prospective cohort. STUDY DESIGN: Cross-sectional study; Level of evidence, 2. METHODS: After training and institutional review board approval, surgeons began enrolling patients undergoing revision ACL reconstruction, recording patient demographics, previous ACL reconstruction methods, intra-articular injuries, and current revision techniques. Enrolled subjects completed a questionnaire consisting of validated patient-based outcome measures. RESULTS: As of April 1, 2009, 87 surgeons have enrolled a total of 460 patients (57% men; median age, 26 years). For 89%, the reconstruction was the first revision. Mode of failure as deemed by the revising surgeon was traumatic (32%), technical (24%), biologic (7%), combination (37%), infection (<1%), and no response (<1%). Previous graft present at the time of injury was 70% autograft, 27% allograft, 2% combination, and 1% unknown. Sixty-two percent were more than 2 years removed from their last reconstruction. Graft choice for revision ACL reconstruction was 45% autograft, 54% allograft, and more than 1% both allograft and autograft. Meniscus and/or chondral damage was found in 90% of patients. CONCLUSION: The MARS Group has been able to quickly accumulate the largest revision ACL reconstruction cohort reported to date. Traumatic reinjury is deemed by surgeons to be the most common single mode of failure, but a combination of factors represents the most common mode of failure. Allograft graft choice is more common in the revision setting than autograft. Concomitant knee injury is extremely common in this population.
BACKGROUND: Revision anterior cruciate ligament (ACL) reconstruction has worse outcomes than primary reconstructions. Predictors for these worse outcomes are not known. The Multicenter ACL Revision Study (MARS) Group was developed to perform a multisurgeon, multicenter prospective longitudinal study to obtain sufficient subjects to allow multivariable analysis to determine predictors of clinical outcome. PURPOSE: To describe the formation of MARS and provide descriptive analysis of patient demographics and clinical features for the initial 460 enrolled patients to date in this prospective cohort. STUDY DESIGN: Cross-sectional study; Level of evidence, 2. METHODS: After training and institutional review board approval, surgeons began enrolling patients undergoing revision ACL reconstruction, recording patient demographics, previous ACL reconstruction methods, intra-articular injuries, and current revision techniques. Enrolled subjects completed a questionnaire consisting of validated patient-based outcome measures. RESULTS: As of April 1, 2009, 87 surgeons have enrolled a total of 460 patients (57% men; median age, 26 years). For 89%, the reconstruction was the first revision. Mode of failure as deemed by the revising surgeon was traumatic (32%), technical (24%), biologic (7%), combination (37%), infection (<1%), and no response (<1%). Previous graft present at the time of injury was 70% autograft, 27% allograft, 2% combination, and 1% unknown. Sixty-two percent were more than 2 years removed from their last reconstruction. Graft choice for revision ACL reconstruction was 45% autograft, 54% allograft, and more than 1% both allograft and autograft. Meniscus and/or chondral damage was found in 90% of patients. CONCLUSION: The MARS Group has been able to quickly accumulate the largest revision ACL reconstruction cohort reported to date. Traumatic reinjury is deemed by surgeons to be the most common single mode of failure, but a combination of factors represents the most common mode of failure. Allograft graft choice is more common in the revision setting than autograft. Concomitant knee injury is extremely common in this population.
Authors: Warren R Dunn; Brian R Wolf; Annunziato Amendola; Jack T Andrish; Christopher Kaeding; Robert G Marx; Eric C McCarty; Richard D Parker; Rick W Wright; Kurt P Spindler Journal: Am J Sports Med Date: 2004-12 Impact factor: 6.202
Authors: J Michael Hardin; Lesa L Woodby; Myra A Crawford; Richard A Windsor; Thomas M Miller Journal: Public Health Nurs Date: 2005 Jul-Aug Impact factor: 1.462
Authors: Rick W Wright; Warren R Dunn; Annunziato Amendola; Jack T Andrish; David C Flanigan; Morgan Jones; Christopher C Kaeding; Robert G Marx; Matthew J Matava; Eric C McCarty; Richard D Parker; Armando Vidal; Michelle Wolcott; Brian R Wolf; Kurt P Spindler Journal: J Knee Surg Date: 2007-10 Impact factor: 2.757
Authors: Rick W Wright; Warren R Dunn; Annunziato Amendola; Jack T Andrish; John Bergfeld; Christopher C Kaeding; Robert G Marx; Eric C McCarty; Richard D Parker; Michelle Wolcott; Brian R Wolf; Kurt P Spindler Journal: Am J Sports Med Date: 2007-04-23 Impact factor: 6.202
Authors: Gonzalo Samitier; Alejandro I Marcano; Eduard Alentorn-Geli; Ramon Cugat; Kevin W Farmer; Michael W Moser Journal: Arch Bone Jt Surg Date: 2015-10
Authors: T Sean Lynch; Richard D Parker; Ronak M Patel; Jack T Andrish; Kurt P Spindler; Annunziata Amendola; Robert H Brophy; Warren R Dunn; David C Flanigan; Laura J Huston; Morgan H Jones; Christopher C Kaeding; Robert G Marx; Matthew J Matava; Eric C McCarty; Angela D Pedroza; Emily K Reinke; Brian R Wolf; Rick W Wright Journal: J Am Acad Orthop Surg Date: 2015-02-09 Impact factor: 3.020
Authors: John P Bigouette; Erin C Owen; Brett Brick A Lantz; Rudolf G Hoellrich; Laura J Huston; Amanda K Haas; Christina R Allen; Allen F Anderson; Daniel E Cooper; Thomas M DeBerardino; Warren R Dunn; Barton Mann; Kurt P Spindler; Michael J Stuart; Rick W Wright; John P Albright; Annunziato Ned Amendola; Jack T Andrish; Christopher C Annunziata; Robert A Arciero; Bernard R Bach; Champ L Baker; Arthur R Bartolozzi; Keith M Baumgarten; Jeffery R Bechler; Jeffrey H Berg; Geoffrey A Bernas; Stephen F Brockmeier; Robert H Brophy; Charles A Bush-Joseph; J Brad Butler; John D Campbell; James L Carey; James E Carpenter; Brian J Cole; Jonathan M Cooper; Charles L Cox; R Alexander Creighton; Diane L Dahm; Tal S David; David C Flanigan; Robert W Frederick; Theodore J Ganley; Elizabeth A Garofoli; Charles J Gatt; Steven R Gecha; James Robert Giffin; Sharon L Hame; Jo A Hannafin; Christopher D Harner; Norman Lindsay Harris; Keith S Hechtman; Elliott B Hershman; Timothy M Hosea; David C Johnson; Timothy S Johnson; Morgan H Jones; Christopher C Kaeding; Ganesh V Kamath; Thomas E Klootwyk; Bruce A Levy; C Benjamin Ma; G Peter Maiers; Robert G Marx; Matthew J Matava; Gregory M Mathien; David R McAllister; Eric C McCarty; Robert G McCormack; Bruce S Miller; Carl W Nissen; Daniel F O'Neill; Brett D Owens; Richard D Parker; Mark L Purnell; Arun J Ramappa; Michael A Rauh; Arthur C Rettig; Jon K Sekiya; Kevin G Shea; Orrin H Sherman; James R Slauterbeck; Matthew V Smith; Jeffrey T Spang; Steven J Svoboda; Timothy N Taft; Joachim J Tenuta; Edwin M Tingstad; Armando F Vidal; Darius G Viskontas; Richard A White; James S Williams; Michelle L Wolcott; Brian R Wolf; James J York Journal: Am J Sports Med Date: 2019-06-21 Impact factor: 6.202
Authors: Richard C Mather; Lane Koenig; Mininder S Kocher; Timothy M Dall; Paul Gallo; Daniel J Scott; Bernard R Bach; Kurt P Spindler Journal: J Bone Joint Surg Am Date: 2013-10-02 Impact factor: 5.284
Authors: Robert A Magnussen; Christophe Trojani; Lars-Petter Granan; Philippe Neyret; Philippe Colombet; Lars Engebretsen; Rick W Wright; Christopher C Kaeding Journal: Knee Surg Sports Traumatol Arthrosc Date: 2014-05-22 Impact factor: 4.342
Authors: Christopher Nagelli; Samuel Wordeman; Stephanie Di Stasi; Joshua Hoffman; Tiffany Marulli; Timothy E Hewett Journal: Am J Sports Med Date: 2018-08-03 Impact factor: 6.202